JP2018506995A5 - - Google Patents

Download PDF

Info

Publication number
JP2018506995A5
JP2018506995A5 JP2017562971A JP2017562971A JP2018506995A5 JP 2018506995 A5 JP2018506995 A5 JP 2018506995A5 JP 2017562971 A JP2017562971 A JP 2017562971A JP 2017562971 A JP2017562971 A JP 2017562971A JP 2018506995 A5 JP2018506995 A5 JP 2018506995A5
Authority
JP
Japan
Prior art keywords
cells
transgene
cell
sequence encoding
dhfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017562971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506995A (ja
JP6947647B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/019288 external-priority patent/WO2016138091A2/en
Publication of JP2018506995A publication Critical patent/JP2018506995A/ja
Publication of JP2018506995A5 publication Critical patent/JP2018506995A5/ja
Application granted granted Critical
Publication of JP6947647B2 publication Critical patent/JP6947647B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017562971A 2015-02-24 2016-02-24 遺伝子改変t細胞の選択方法 Active JP6947647B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562120329P 2015-02-24 2015-02-24
US62/120,329 2015-02-24
US201562120790P 2015-02-25 2015-02-25
US62/120,790 2015-02-25
US201562175794P 2015-06-15 2015-06-15
US62/175,794 2015-06-15
PCT/US2016/019288 WO2016138091A2 (en) 2015-02-24 2016-02-24 Selection methods for genetically-modified t cells

Publications (3)

Publication Number Publication Date
JP2018506995A JP2018506995A (ja) 2018-03-15
JP2018506995A5 true JP2018506995A5 (enExample) 2019-03-14
JP6947647B2 JP6947647B2 (ja) 2021-10-13

Family

ID=56464271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017562971A Active JP6947647B2 (ja) 2015-02-24 2016-02-24 遺伝子改変t細胞の選択方法

Country Status (8)

Country Link
US (2) US10808230B2 (enExample)
EP (2) EP3804741A3 (enExample)
JP (1) JP6947647B2 (enExample)
KR (1) KR20170117095A (enExample)
CN (1) CN107667169B (enExample)
AU (2) AU2016222850B2 (enExample)
CA (1) CA2976126A1 (enExample)
WO (1) WO2016138091A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3974520A1 (en) 2013-05-14 2022-03-30 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CA3190002A1 (en) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
WO2016073629A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
CA2977818A1 (en) 2015-03-11 2016-09-15 Board Of Regents, The University Of Texas System Transposase polypeptides and uses thereof
KR20180042449A (ko) 2015-09-15 2018-04-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 T 세포 수용체(tcr) 결합 항체 및 이의 용도
EP3368075B1 (en) 2015-10-27 2020-01-29 Board of Regents, The University of Texas System Chimeric antigen receptor molecules and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
CN109136282A (zh) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 一种hafft1细胞的构建方法
WO2020102726A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Method for manufacturing of human hybrid regulatory t/th2 cells (hybrid treg/th2 cells) from de-differentiated t cells
CN113573778B (zh) 2018-11-16 2025-05-13 拉帕治疗有限公司 使用诱导性调节性T(iTREG)细胞进行的ALS治疗
KR102594009B1 (ko) 2021-02-01 2023-10-24 서울대학교산학협력단 형질전환 생식세포의 제조 방법 및 이를 이용한 형질전환 동물의 제조 방법
JP2024533772A (ja) * 2021-09-30 2024-09-12 ユニバーシティ オブ サザン カリフォルニア ヒト肝細胞培養培地およびin vitro培養ヒト肝細胞の馴化培地ならびにその使用
CN114740196B (zh) * 2022-04-08 2023-04-18 中南大学湘雅二医院 标志物及其在制备评价机体免疫功能的产品中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101361416B1 (ko) * 2008-10-08 2014-02-21 인트렉손 코포레이션 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
ES2743507T3 (es) * 2009-11-02 2020-02-19 Univ Emory Inmunoterapia resistente a fármaco para el tratamiento de un cáncer
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US8809017B2 (en) * 2011-05-24 2014-08-19 Agency For Science, Technology And Research IRES mediated multicistronic vectors
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
EP3594245A1 (en) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
EP3974520A1 (en) 2013-05-14 2022-03-30 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CN105848484A (zh) 2013-10-25 2016-08-10 得克萨斯州大学系统董事会 用于免疫治疗的多克隆γδ T细胞
EP3071687B1 (en) * 2013-11-22 2019-07-31 Cellectis Method of engineering chemotherapy drug resistant t-cells for immunotherapy
CA3190002A1 (en) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
AU2015243849B2 (en) * 2014-04-10 2020-12-17 Seattle Children's Hospital (dba Seattle Children's Research Institute) Transgene genetic tags and methods of use
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
WO2015164740A1 (en) 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
WO2016073629A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
KR20170075785A (ko) 2014-11-05 2017-07-03 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포
CA2977818A1 (en) 2015-03-11 2016-09-15 Board Of Regents, The University Of Texas System Transposase polypeptides and uses thereof
KR20180042449A (ko) 2015-09-15 2018-04-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 T 세포 수용체(tcr) 결합 항체 및 이의 용도
EP3368075B1 (en) 2015-10-27 2020-01-29 Board of Regents, The University of Texas System Chimeric antigen receptor molecules and uses thereof

Similar Documents

Publication Publication Date Title
Krueger et al. Two sequential activation modules control the differentiation of protective T helper-1 (Th1) cells
US10472637B2 (en) Gold optimized CAR T-cells
Fazilleau et al. The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding
Schrama et al. Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue
Gattinoni et al. T memory stem cells in health and disease
Stritesky et al. The transcription factor STAT3 is required for T helper 2 cell development
US11723962B2 (en) Cell-based neoantigen vaccines and uses thereof
JP2022043043A (ja) 免疫細胞の有効性および増大を改善する方法
CN111989108B (zh) 利用rna去稳定元件协调基因表达
CN115697387A (zh) 抗bcma嵌合抗原受体的用途
BR112020007710A2 (pt) métodos para produzir células que expressam receptor de antígeno quimérico
WO2018102761A1 (en) Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
CN109121413A (zh) 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法
CA3026180A1 (en) Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
US20180298349A1 (en) Selection methods for genetically-modified t cells
AU2015339106A1 (en) Compositions and methods of stimulating and expanding T cells
US20220152107A1 (en) Method for expansion and differentiation of t lymphocytes and nk cells for adoptive transfer therapies
Beltra et al. Enhanced STAT5a activation rewires exhausted CD8 T cells during chronic stimulation to acquire a hybrid durable effector like state
US20220241333A1 (en) Modulation of t cell cytotoxicity and related therapy
Trella et al. CD40 ligand‐expressing recombinant vaccinia virus promotes the generation of CD8+ central memory T cells
Metcalfe et al. Ag85A-specific CD4+ T cell lines derived after boosting BCG-vaccinated cattle with Ad5-85A possess both mycobacterial growth inhibition and anti-inflammatory properties
US9234175B2 (en) Creating bioengineered lymph nodes
Curtis et al. Fidelity of pathogen-specific CD4+ T cells to the Th1 lineage is controlled by exogenous cytokines, interferon-γ expression, and pathogen lifestyle
Muthuvel et al. Engineering safe anti-CD19-CD28ζ CAR T cells with CD8a hinge domain in serum-free media for adoptive immunotherapy
TW202400780A (zh) Cd16highcd57highnk-92mi 細胞